1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Order Moxifloxacin (Avelox) 400mg Without Prescription

Buy Avelox Online With Low Price

Support Drug Guide: purchase the best generic medicine from our sponsor, online pharmacy store, where you can place an order and buy generic Avelox online over the counter at lowest prices, worldwide delivery. Prices for Avelox (Moxifloxacin) according to the dosage forms and number of pills. The more pills in a package, the lower the price for 1 pill!

Buy Avelox with VISA Buy generic Avelox with MasterCard Bitcoint Secured by GeoTrust SSL: We offer the highest grade, 256-bit strength SSL Certificates through our official partner, GeoTrust. Online Pharmacy continues to meet the highest standards in the field of security with the implementation of McAfee Secure (formally Hacker Safe), the leading security certification service and provider on the Internet. Security Metrics: Certified and Credit Card Safe transactions. Generic Avelox as effective as brand-name drug! Shipping: Avelox delivery by U.S. Postal Service

The price of the product includes the shipping rate 9.95$.

Buy Moxifloxacin Online

Moxifloxacin is authorised in the world under the following brand names: Avelox, Avelox I.V., Vigamox.

Where to buy Avelox in the USA? Where can you buy Moxifloxacin OTC in the UK? Moxifloxacin for sale in Australia How much does Avelox cost without insurance from Canada? Price of generic Moxifloxacin in France Buy generic Avelox from India online for the cheapest prices Cheap Moxifloxacin is available to buy in Ireland Order Moxifloxacin in Italy online How to buy Moxifloxacin for cheap in New Zealand? Can you buy Moxifloxacin over the counter in Spain?



Moxifloxacin (Bayer's Avelox) is a fluoroquinolone used for the treatment of respiratory tract infections including acute exacerbations of chronic bronchitis. In December 1999, the FDA approved the oral formulation of moxifloxacin, and in December 2001, the agency approved the parenteral formulation of this product for the same indications. In Germany, oral moxifloxacin received regulatory approval in September 1999 for the treatment of community-acquired infections, including acute exacerbations of chronic bronchitis. The parenteral formulation was approved in May 2002. Oral moxifloxacin was recently launched in Spain and Italy and is awaiting regulatory approval in other European markets. In Japan, moxifloxacin is in Phase III and Phase I trials for the oral and IV formulations, respectively. This agent will retain patent protection through 2014 in the United States and through 2009 in Europe and Japan. Moxifloxacin displays excellent activity against a broad spectrum of bacteria, including penicillin- and macrolide-resistant S. pneumoniae. It is highly active against the following:

  • Common RTI pathogens such as S. pneumoniae, H. influenzae, and M. catarrhalis.
  • RTI pathogens with reduced susceptibility to conventional agents such as penicillin and macrolide-resistant strains of S. pneumoniae.
  • Unusual community RTI pathogens such as Staphylococcus aureus and K. pneumoniae.
  • Atypical microorganisms, such as Mycoplasma, Legionella, and Chlamydia.

Moxifloxacin offers superior activity against S. pneumoniae compared with that of current quinolones (e.g., ciprofloxacin, levofloxacin) and is extremely effective in treating other respiratory pathogens. A multi-center, multinational, randomized, double-blind Phase III study compared moxifloxacin with amoxicillin in patients experiencing acute exacerbations of chronic bronchitis. During a 12-month monitoring period, 730 patients with acute exacerbations of chronic bronchitis were randomized to receive moxifloxacin (400 mg, once daily, for five days) or a standard treatment regimen consisting of amoxicillin (500 mg, three times daily, for seven days) or clarithromycin (500 mg, twice daily, for seven days) or the cephalosporin cefuroxime axetil (250 mg, twice daily, for seven days).


The primary end point was clinical success (resolution and improvement) at 7-10 days post treatment. Patients were also monitored after nine months to assess long-term outcomes, including time until their next exacerbation. Moxifloxacin demonstrated a significantly higher clinical cure rate (70.9% versus 62.8% in the comparator arm) and a significantly higher bacteriological response rate (92% versus 81% in the comparator arm). A follow-up study showed that for patients who received moxifloxacin, the average interval between episodes of acute exacerbations of chronic bronchitis was approximately two weeks longer than for those who received standard therapy. Moxifloxacin is not associated with phototoxicity, but it has been shown to alter the QT interval above baseline. The frequency and severity of adverse reactions were equal to those experienced among the comparators (clarithromycin and cefuroxime axetil) and included nausea (8%), diarrhea (6%), and dizziness (3%).

Buy Most Popular Antibiotic, Antifungal, Antiparasitic, Antiviral Drugs Online

Bactrim 400+80, 800+160 mg (Co-trimoxazole) Cipro 250, 500, 750, 1000 mg (Ciprofloxacin)
Diflucan 50, 100, 150, 200 mg (Fluconazole) Flagyl 200, 400 mg (Metronidazole)
Grifulvin 250 mg (Griseofulvin) Levaquin 250, 500, 750 mg (Levofloxacin)
Nizoral 200 mg (Ketoconazole) Sporanox 100 mg (Itraconazole)
Vermox 100 mg (Mebendazole) Amoxil 250, 500 mg (Amoxicillin)
Dosage forms of Moxifloxacin:
Avelox abc pack 400 mg tablet Avelox 400 mg tablet Vigamox 0.5% eye drops Vigamox 0.5% Solution 3ml Bottle
Avelox iv 400 mg/250 ml      

Synonyms of Moxifloxacin:

BAY 12-8039, Moxifloxacin, Moxifloxacin HCl, Moxifloxacin Hydrochloride

How can i get Moxifloxacin online over the counter?

You can buy Moxifloxacin OTC in online drugstore with low cost.

Therapeutic classes of Moxifloxacin:

Anti-Bacterial Agents, Anti-Infective Agents, Quinolones


Australia, Canada, Mexico, New Zealand, USA, Europe [Belgium, France, Norway, Holland, Ireland, Spain, Switzerland, Great Britain (UK), Italy] and etc.

Leave a Reply

Notify of